Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Creative Commons License

ÖZGÜROĞLU M., Kilickap S., Sezer A., GÜMÜŞ M., Bondarenko I., Gogishvili M., ...Daha Fazla

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33, (Özet Bildiri) identifier